Psychopharmacology in dermatological practice: A review and update

Dermatology and Psychosomatics

Volumn 4, Issue 3, 2003, Pages 131-140

  Lee, Ernest ^a   Murase, J ^a   Koo, J ^a   Lee, C S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anxiety; Depression; Obsessive compulsive disorder; Psychopharmacology; Psychosis

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ASTEMIZOLE; BENZATROPINE MESILATE; BENZODIAZEPINE; BUSPIRONE; CHLORDIAZEPOXIDE; CISAPRIDE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DERMATOLOGICAL AGENT; DESIPRAMINE; DIAZEPAM; DIPHENHYDRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; GABAPENTIN; HYDROXYZINE; IMIPRAMINE; NEFAZODONE; OLANZAPINE; PAROXETINE; PIMOZIDE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTRALINE; TERFENADINE; UNINDEXED DRUG; VENLAFAXINE;

ABDOMINAL DISCOMFORT; AGITATION; AKATHISIA; ANOREXIA; ANXIETY DISORDER; CARDIOTOXICITY; CAUSE OF DEATH; CLINICAL TRIAL; CONSTIPATION; DELUSIONAL DISORDER; DEPRESSION; DERMATOLOGY; DIARRHEA; DROWSINESS; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INCREASED APPETITE; INSOMNIA; LIVER TOXICITY; MENTAL DISEASE; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; ORGASM DISORDER; ORTHOSTATIC HYPOTENSION; PRIAPISM; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOSIS; PSYCHOSOMATIC DISORDER; REVIEW; RHINITIS; SEIZURE; SOMNOLENCE; SUSTAINED DRUG RELEASE; SWEATING; TARDIVE DYSKINESIA; TORSADE DES POINTES; TREMOR; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0141993300     PISSN: 14229196     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073989     Document Type: Review

References (72)

1. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. Washington, DC, 1994, pp 444-448.
2. American Psychiatric Association. DSM-IV-TR: Diagnostic and Statistical Manual of Mental Disorders. Washington, DC, 2000.
3. Arvanitis LA, Miller BG: ICI 204, 636, an atypical antipsychotic: Results from a multiple-fixed dose, placebo-controlled trial (abstract). Psychopharmacol Bull 1997a;23:567-582.
4. Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group: Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997b;42:233-246.
5. Bernstein JE, Whitney DH, Soltani K: Inhibition of histamine-induced pruritus by topical tricyclic anti-depressant. J Am Acad Dermatol 1981;5:582-585.
6. Bernstein JE, Swift RM, Soltani K, Lorincz AL: Antipruritic effect of an opiate antagonist, naloxone hydrochloride. J Invest Dermatol 1982;78:82-3.
7. Bishop ER Jr: Monosymptomatic hypochondriacal syndromes in dermatology. J Am Acad Dermatol 1983;9:152-158.
8. Brawman-Mintzer O, Lydiard RB: Psychopharmacology of anxiety disorders. Psychiatr Clin North Am 1994;1:51-79.
9. Boyer WF: Potential indications for the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol. 1992;6(suppl 5):5-12.
10. Bueller HA, Bernhard JD, Dubroff LM: Gabapentin treatment for brachioradial pruritus. J Eur Acad Derm Venereo 1999;13:227-230.
11. Clerc GE, Ruimy P, Verdeau-Pailles J: A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-143.
12. Damiani JT, Flowers FP, Pierce DK: Pimozide in delusions of parasitosis. J Am Acad Dermatol 1990;22: 312-313.
13. Davidson J: Seizures and bupropion: A review. J Clin Psychiatry 1989;50:256-261.
14. Davidson JR, DuPont RL, Hedges D, Haskins JT: Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999;60: 528-535.
15. De Leon OA, Furmaga KM, Canterbury AL, Bailey LG: Risperidone in the treatment of delusions of infestation. Int J Psychiatry Med 1997;27:403-409.
16. Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS: Mechanisms of action of atypical antipsychotic drugs: Implications for novel therapeutic strategies for schizophrenia. Schizophr Res 1991;4:121-156.
17. Driscoll MS, Rothe MJ, Grant-Kels JM, Hale MS: Delusional parasitosis: A dermatologic, psychiatric, and pharmacologic approach. J Am Acad Dermatol 1993;29:1023-1033.
18. Eberhard G, von Knorring L, Nilsson HL, Sundequist U, Bjorling G, Linder H, Svard KO, Tysk L: A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes. Neuropsychobiology 1988;19:25-34.
19. Elmer KB, George RM, Paterson K: Therapeutic update: Use of risperidone for the treatment of monosymptomatic hypochondriacal psychosis. J Am Acad Dermatol 2000;43:683-686.
20. Fawcett J, Marcus RN, Anton SF, O'Brien K, Schwiderski U: Response of anxiety and agitation symptoms during nefazaodone treatment of major depression. J Clin Psychiatry 1995;56:37-42.
21. Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS: Nefazodone versus sertraline in out-patients with major depression: Focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996;57(suppl 2):53-62.
22. Feinmann C, Harris M, Cawley R: Psychogenic facial pain: Presentation and treatment. BMJ 1984;288: 436-438.
23. Figueiredo A, Ribeiro CA, Goncalo M, Almeida L, Poiares-Baptista A, Teixeira F: Mechanism of action of doxepin in the treatment of chronic urticaria. Fundam Clin Pharmacol 1990;4:147-158.
24. Friedel RO, Raskind MA: Relationship of blood levels of Sinequan to clinical effects in the treatment of depression in aged patients; in Mendels J (ed): A Monograph of Recent Clinical Studies. Lawrenceville, NJ, Excerpta Medica, 1975.
25. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E: Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 2000;283:3082-3088.
26. Gerlach J: New antipsychotics: Classifications, efficacy and adverse effects. Schizophr Bull 1991;17:289-309.
27. Grimsley SR, Jann MW: Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors. Clin Pharm 1992;11:930-957.
28. Hamann K, Avnstorp L: Delusions of infestation treated by pimozide: A double-blind crossover clinical study. Acta Derm Venereol 1982;62:55-58.
29. Hansen TE, Casey DE, Hoffman WF: Neuroleptic intolerance. Schizophr Bull 1997;23:567-582.
30. Haskell DS, Gambill JD, Gardos G, McNair DM, Fisher S: Doxepin or diazepam for anxious and anxious-depressed outpatients? J Clin Psychiatry 1978; 39:135-139.
31. Hoehn-Saric R, McLeod DR, Zimmerli WD: Differential effects of alprazolam and imipramine in generalized anxiety disorder: Somatic versus psychic symptoms. J Clin Psychiatry 1988;49:293-301.
32. Holmes VF: Treatment of monosymptomatic hypochondriacal psychosis with pimozide in an AIDS patient (letter). Am J Psychiatry 1989;146:554-555.
33. Kavoussi RJ, Segraves RT, Hughes AR, Ascher JA, Johnston JA: Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997;58:532-537.
34. Kishore-Kumar R, Max MB, Schafer SC, Gaughan AM, Smoller B, Gracely RH, Dubner R: Desipramine relieves postherpetic neuralgia. Clin Pharmacol Ther 1990;47:305-312.
35. Koblenzer CS: Noncutaneous manifestations of skin diseases: Psychological aspects of skin disease; in Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz S (eds): Dermatology in General Medicine. New York, McGraw Hill, 1999, vol 1, pp 475-486.
36. Koblenzer CS: The use of psychotropic drugs in dermatology. Dermatol Psychosom 2001;2:167-176.
37. Koo J, Gambla C: Delusions of parasitosis and other forms of monosymptomatic hypochondriacal psychosis. Dermatol Clin 1996;14:429-438.
38. Koo JYM, Lee CS: Psychotropic agents; in Wolverton SE (ed): Comprehensive Dermatologic Therapy. W.B. Saunders, 2001, pp 402-425.
39. Koo JYM, Strauss GD: Psychopharmacologic treatment of psychocutaneous disorders: A practical guideline. Semin Dermatol 1987;6:83-93.
40. Lecrubier Y, Bourin M, Moon CA, Schifano F, Blan-chard C, Danjou P, Hackett D: Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 1997;95:485-493.
41. Leonard HL: New developments in the treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(suppl 14):39-45.
42. Lieberman JA: Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1993;54(suppl): 13-17.
43. Lindskov R, Baadsgaard O: Delusions of infestation treated with pimozide: A follow-up study. Acta Derm Venereol 1985;65:267-270.
44. Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH: Amitriptyline, but not lorazepam, relieve postherpetic neuralgia. Neurology 1988;38: 1427-1432.
45. Meltzer HY: New drugs for the treatment of schizophrenia. Psychiatr Clin North Am 1993;16:365-385.
46. Modell JG, Katholi CR, Modell JD, DePalma RL: Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline. Clin Pharmacol Ther 1997;61:476-487.
47. Montgomery SA: Venlafaxine: A new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993;54:119-126.
48. Monti M, Sambvani N, Sacrini F: Obsessive-compulsive disorders in dermatology. J Eur Acad Derm Venereol 1998;11:103-108.
49. Munro A: Monosymptomatic hypochondriacal psychosis. Br J Psychiatry 1988;153(suppl):37-40.
50. Munro A, Chmars J: Monosymptomatic hypochondriacal psychosis: A diagnostic checklist based on 50 cases of the disorder. Can J Psychol 1982;27:374-376.
51. Physicians' desk reference, ed 56. Oradell, NJ, Medical Economics Company, 2002a, pp 1407.
52. Physicians' desk reference, ed 56. Oradell, NJ, Medical Economics Company, 2002b, pp 1680.
53. Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, Iyengar MK: Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001;62:350-357.
54. Rasmussen SA, Eisen JL: Treatment strategies for chronic and refractory obsessive-compulsive disorder. J Clin Psychiatry 1997;58(suppl 13):9-13.
55. Remick RA, Keller FD, Buchanan RA, Gibson RE, Fleming JA: A comparison of the efficacy and safety of alprazolam and desipramine in depressed outpatients. Can J Psychiatry 1988;33:590-594.
56. Richelson E: Antidepressants and brain neurochemistry. Mayo Clin Proc 1990;65:1227-1236.
57. Richelson E: Biological basis of depression and therapeutic relevance. J Clin Psychiatry 1991;52(suppl): 4-10.
58. Rickels K, Pollack MH, Sheehan DV, Haskins JT: Efficacy of extended-release Venlafaxine in nonde-pressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000;157:968-974.
59. Romach M, Busto U, Somer G, Kaplan HL, Sellers E: Clinical aspects of chronic use of alprazolam and lorazepam. Am J Psychiatry 1995;152:1161-1167.
60. Savin JA, Paterson WD, Adam K, Oswald I: Effects of trimeprazine and trimipramine on nocturnal scratching in patients with atopic eczema. Arch Dermatol 1979;115:313-315.
61. Schatzberg AF, Cole JO: Benzodiazepines in depressive disorders. Arch Gen Psychiatry 1978;35:1359-1365.
62. Schatzberg AF, Cole JO, Degattista C: Antipsychotic Drugs; in Schatzberg AF, DeBattista C, Cole JO (eds): Manual of Clinical Psychopharmacology. Washington, DC, APA Press 1997, ed 2, pp 154-155.
63. Schmelz M: Itch - mediators and mechanisms. J Dermatol Sci 2002;28:91-96.
64. Settle EC Jr: Antidepressant drugs: Disturbing and potentially dangerous adverse effects. J Clin Psychiatry 1998;59(suppl 16):25-30.
65. Silverstone PH, Ravindran A, for the Venlafaxine XR 360 Canadian Study Group: Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. J Clin Psychiatry 1999;60:22-28.
66. Stangier U, Janich C, Adam-Schwebe S, Berger P, Wolter M: Screening for body dysmorphic disorder in dermatological outpatients. Dermatol Psychosom 2003;4:66-71.
67. Tariot PN, Salzman C, Yeung PP, Pultz J, Rak IW: Long-term use of quatiapine in elderly patients with psychotic disorders. Clin Ther 2000;22:1068-1084.
68. Tasman A: Psychiatry. W.B. Saunders, 1997, ed 1, pp 1110-1115.
69. Urban BJ, France RD, Steinberger EK, Scott DL, Maltbie AA: Long-term use of narcotic/antidepressant medication in the management of phantom limb pain. Pain 1986;24:191-196.
70. Watson CP, Evans RJ, Reed K, Merskey H, Goldsmith L, Warsh J: Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982;32:671-673.
71. Watson CPN, Chipman M, Reed K, Evans RJ, Birkett N: Amitriptyline versus maprotiline in postherpetic neuralgia: A randomized, double-blind crossover trial. Pain 1992;48:29-36.
72. Zajecka JM: The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings. J Clin Psychiatry 1996;57:10-14.